No abstract

Substituting differently the two aromatic rings of bis(phenolato)-bis(alkoxo) ligands yields C1-symmetrical titanium(iv) complexes that are highly soluble and stable in biological media and display marked cytotoxicity toward various cancer cells.

Vanadium complexes are attractive potential alternatives to platinum-based anticancer drugs. Two vanadium(V) complexes, based on a common chelating tetradentate diaminobis(phenolato) ligand featuring a branched connectivity but differing in their labile ligands, were synthesized and characterized. Whereas the isopropoxido complex was obtained as a mixture of cis and trans isomers with regard to the orientation of the labile group vs. the amine sidearm, the salicylato-containing complex was obtained as a single trans isomer. X-ray

Orally administered anticancer drugs facilitate treatment, but the acidic conditions in the stomach often challenge their availability. PhenolaTi is a TiIV‐based nontoxic anticancer drug with marked in‐vivo efficacy. We report that nanoformulation protects phenolaTi from decomposition in stomach‐like conditions. This is evidenced by similar NMR characteristics and similar in‐vitro cytotoxicity toward murine (CT‐26) and human (HT‐29) colon cancer cells before and after incubation of nanoformulated phenolaTi (phenolaTi‐F) at pH 2, unlike results with the unformulated form of the complex. Furthermore, administration of phenolaTi‐F in animal drinking water revealed a notable inhibition of tumor growth in Balb/c and immune‐deficient (Nude) mice inoculated with CT‐26 and HT‐29 cells, respectively. In‐vivo efficacy was at least similar to that of the corresponding intraperitoneal treatment with phenolaTi‐F and the clinically employed oral drug, capecitabine. No body weight loss or clinical signs of toxicity were evident in the phenolaTi‐F‐treated animals. These findings demonstrate a new convenient mode of cancer treatment through oral administration by safe titanium‐based drugs.